Emil Kakkis

Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference

Retrieved on: 
Thursday, June 3, 2021
Ultragenyx, Emil Kakkis, Companies, Economy of the United States

NOVATO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Goldman Sachs 42nd Annual Healthcare Conference on Thursday, June 10, 2021 at 3:00 PM ET.

Key Points: 
  • NOVATO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Goldman Sachs 42nd Annual Healthcare Conference on Thursday, June 10, 2021 at 3:00 PM ET.
  • The live and archived webcast of the presentation will be accessible from the companys website at http://ir.ultragenyx.com/events.cfm .
  • Ultragenyx is a biopharmaceutical company committed to bringing to patients novel therapies for the treatment of serious rare and ultra-rare genetic diseases.
  • The company is led by a management team experienced in the development and commercialization of rare disease therapeutics.

Ultragenyx to Present at Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 26, 2021
Ultragenyx, Emil Kakkis, Geography of California, Novato, California, California, Economy of the United States

NOVATO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 PM ET.

Key Points: 
  • NOVATO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 PM ET.
  • The live and archived webcast of the presentation will be accessible from the companys website at http://ir.ultragenyx.com/events.cfm .
  • Ultragenyx is a biopharmaceutical company committed to bringing to patients novel therapies for the treatment of serious rare and ultra-rare genetic diseases.
  • For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com .

Ultragenyx to Present at Truist Securities Life Sciences Summit

Retrieved on: 
Wednesday, April 28, 2021
Life sciences, Biotechnology, Ultragenyx, Emil Kakkis, Biopharmaceutical, Rare disease

b"NOVATO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., will present at the 7th Annual Truist Securities Life Sciences Summit on Wednesday, May 5, 2021 at 1:00 PM ET.\nThe live and archived webcast of the presentation will be accessible from the company\xe2\x80\x99s website at http://ir.ultragenyx.com/events.cfm .

Key Points: 
  • b"NOVATO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., will present at the 7th Annual Truist Securities Life Sciences Summit on Wednesday, May 5, 2021 at 1:00 PM ET.\nThe live and archived webcast of the presentation will be accessible from the company\xe2\x80\x99s website at http://ir.ultragenyx.com/events.cfm .
  • The replay of the webcast will be available for 90 days.\nUltragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases.
  • The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.\nThe company is led by a management team experienced in the development and commercialization of rare disease therapeutics.
  • Ultragenyx\xe2\x80\x99s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.\nFor more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com .\n"

Ultragenyx to Present at Barclays Global Healthcare Conference

Retrieved on: 
Wednesday, March 3, 2021
Ultragenyx, Emil Kakkis, Novato, California, Geography of California, California, Economy of the United States

NOVATO, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Barclays Global Healthcare Conference on Wednesday, March 10, 2021 at 4:45 PM ET.

Key Points: 
  • NOVATO, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Barclays Global Healthcare Conference on Wednesday, March 10, 2021 at 4:45 PM ET.
  • The live and archived webcast of the presentation will be accessible from the companys website at http://ir.ultragenyx.com/events.cfm .
  • Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases.
  • For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com .

Ultragenyx to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

Retrieved on: 
Tuesday, January 5, 2021
Ultragenyx, Emil Kakkis, Economy of the United States

NOVATO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 12, 2021 at 2:50 pm EST.

Key Points: 
  • NOVATO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 12, 2021 at 2:50 pm EST.
  • The live and archived webcast of the presentation will be accessible from the companys website at http://ir.ultragenyx.com/events.cfm .
  • Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases.
  • The company is led by a management team experienced in the development and commercialization of rare disease therapeutics.

Inventiva announces positive results from Phase IIa clinical study with odiparcil in mucopolysaccharidosis type VI

Retrieved on: 
Wednesday, December 18, 2019
Health, Clinical research, Design of experiments, Clinical pharmacology, Clinical trial, Pharmaceutical industry, Medical research, Emil Kakkis, Iduronidase

The 26-week Phase IIa clinical trial included 20 patients aged 16 years or older suffering from advanced stages of MPS VI.

Key Points: 
  • The 26-week Phase IIa clinical trial included 20 patients aged 16 years or older suffering from advanced stages of MPS VI.
  • The clinical study met its safety primary objective further supporting the good overall safety profile of odiparcil already observed in previous Phase I and Phase II clinical studies conducted for the prevention of thrombosis.
  • Based on the iMProveS clinical study results, Inventiva has decided to continue the clinical development of odiparcil for the treatment of MPS VI.
  • The iMProveS (improve MPS treatment) study was a 26-week Phase IIa clinical trial taking place in four European sites and evaluating odiparcil for the treatment of patients with mucopolysaccharidosis (MPS) type VI.

CANbridge Pharmaceuticals’ Hunterase® Granted Priority Review by the Chinese National Medical Products Administration

Retrieved on: 
Tuesday, September 10, 2019
Biotechnology, Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Health, Articles, Life sciences, Iduronate-2-sulfatase, Syndromes, Mucopolysaccharidosis, Priority review, Hunter syndrome, Pharmaceutical industry in China, Biopharmaceutical, Rare disease, Emil Kakkis, Hunter syndrome, CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that the National Medical Products Administration (NMPA) of China granted Priority Review to Hunterase (idursulfate beta), a human recombinant iduronate-2-sulfatase (IDS) enzyme replacement therapy, for the treatment of Hunter syndrome (mucopolysaccharidosis type II).

Key Points: 
  • CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that the National Medical Products Administration (NMPA) of China granted Priority Review to Hunterase (idursulfate beta), a human recombinant iduronate-2-sulfatase (IDS) enzyme replacement therapy, for the treatment of Hunter syndrome (mucopolysaccharidosis type II).
  • The Chinese government has included mucopolysaccharidosis on the First National List of Rare Diseases as a disease group to target.
  • The Priority Review designation, solely granted to therapies that address unmet medical conditions with some level of clinical urgency, validates our choice of Hunterase as the first rare disease candidate we plan to commercialize, said James Xue, Ph.D., Founder, Chairman and CEO, CANbridge Pharmaceuticals Inc. Hunterase is approved in 10 countries.
  • Mucopolysaccharidosis is one of the 121 diseases on the First National List of Rare Diseases published by the Chinese government.

Mucopolysaccharidosis I (Hurler Syndrome) Pipeline Analysis, H1 2018 with Profiles of ArmaGen, Angiochem and JCR Pharmaceuticals

Retrieved on: 
Monday, June 4, 2018
Health, Mucopolysaccharidosis, Hurler, Pharmaceutical industry, Clinical trial, Emil Kakkis

The "Mucopolysaccharidosis I (Hurler Syndrome) Pipeline Analysis 2018 (H1) - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mucopolysaccharidosis I (Hurler Syndrome) Pipeline Analysis 2018 (H1) - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments" report has been added to ResearchAndMarkets.com's offering.
  • Mucopolysaccharidosis I (Hurler Syndrome) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
  • Mucopolysaccharidosis I (Hurler Syndrome) Pipeline Analysis report covers 11 drugs currently in different phases of development.
  • Major industry players profiled as part of the report are ArmaGen, Angiochem and JCR Pharmaceuticals Co Ltd among others.